ライフサイエンスコーパス: parenteral

1 tic therapy was 6 weeks, of which 1 week was parenteral.

2 .8% were prescribed systemic steroids (46.1% parenteral, 47.3% oral, 6.6% both).

3 ral drugs (ARVs) were recently developed for parenteral administration at monthly or longer intervals

4 more polar molecules that currently require parenteral administration because the vaginal epithelium

5 for patients, since repetitive and long-term parenteral administration is required as most proteins a

6 Taken together, these data suggest parenteral administration of adjuvanted, inactivated who

7 Parenteral administration of IL-4 resulted in augmented

8 on absorption by activation of HIF-2alpha or parenteral administration of iron-dextran in HIF-2alpha

9 Here we show that long-term parenteral administration of superphysiological doses of

10 d coverage of four childbirth interventions (parenteral administration of uterotonics, antibiotics, a

11 rising fewer injections and oral rather than parenteral administration, compared with a reference tre

12 Furthermore, after parenteral administration, the FhHDM-1 peptide interacte

13 ssing a current need for alternatives to ICG parenteral administration.

14 FpEF, but its use is limited by the need for parenteral administration.

15 f less than 100nm are excellently suited for parenteral administration.

16 ltiple sclerosis and rheumatoid arthritis by parenteral administration.

17 ing in a PK profile suitable for long-acting parenteral administration.

18 ration of rotavirus vaccine for live oral or parenteral administration.IMPORTANCE Mechanisms for in v

19 Compound 12, a promising parenteral agent for the treatment of MET-dependent canc

20 ulants; 4) evaluate whether to bridge with a parenteral agent periprocedurally; 5) offer advice on ho

21 ental introduction of amino acids (Inc-AAs)] parenteral amino acid delivery within 24 h of birth on b

22 In patients with a stable parenteral amino acid supply (n = 7), the median net pro

23 Imm-RDI of parenteral amino acids does not benefit body composition

24 Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-

25 randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, al

26 the human mineral and endocrine response to parenteral and duodenal acute phosphate loads.

27 Daily parenteral and enteral manganese intakes were calculated

28 ediatrics, the ASN, the American Society for Parenteral and Enteral Nutrition, the Academy of Nutriti

29 After controlling for GA, higher parenteral and total manganese intakes were associated w

30 This parenteral antibacterial agent has a dual mechanism of a

31 determine whether there were differences in parenteral antibiotic completion and readmission rates.

32 d patients were followed up by an outpatient parenteral antibiotic therapy (OPAT) service.

33 Parenteral antibiotic therapy for young infants (aged 0-

34 Ceftriaxone is recommended when parenteral antibiotic therapy is recommended.

35 Outpatient parenteral antibiotic treatment (OPAT) has proven effica

36 l infections, and duration of total (or just parenteral) antibiotic sue.

37 ws: 1) blood cultures before antibiotics; 2) parenteral antibiotics administered less than or equal t

38 Drug-induced eosinophilia is common with parenteral antibiotics.

39 We calculated the effect of parenteral anticoagulant administration on all-cause mor

40 red with accelerated infusion alteplase plus parenteral anticoagulants (RR 1.47 [95% CI 1.10-1.98] fo

41 Parenteral anticoagulants administered in doses greater

42 with accelerated infusion of alteplase with parenteral anticoagulants as background therapy, strepto

43 alteplase, tenecteplase, and reteplase with parenteral anticoagulants as background therapy.

44 omparison with conventional anticoagulation (parenteral anticoagulants followed by vitamin K antagoni

45 Hospital utilization rates of parenteral anticoagulants for AF during sepsis varied (m

46 tors; RR 1.88 [1.24-2.86] for reteplase plus parenteral anticoagulants plus glycoprotein inhibitors).

47 .47 [95% CI 1.10-1.98] for tenecteplase plus parenteral anticoagulants plus glycoprotein inhibitors;

48 y for randomised controlled trials comparing parenteral anticoagulants with placebo or standard care

49 .10-1.45] for non-accelerated alteplase plus parenteral anticoagulants).

50 A total of 13611 patients (35.3%) received parenteral anticoagulants, while 24971 (64.7%) did not.

51 14 [95% CI 1.05-1.24] for streptokinase plus parenteral anticoagulants; RR 1.26 [1.10-1.45] for non-a

52 urred more often among patients who received parenteral anticoagulation (1163 of 13505 [8.6%]) than p

53 05 [8.6%]) than patients who did not receive parenteral anticoagulation (979 of 13505 [7.2%]; RR, 1.2

54 ]) and did not (185 of 13505 [1.4%]) receive parenteral anticoagulation (relative risk [RR], 0.94; 95

55 Risk of ischemic stroke associated with parenteral anticoagulation did not differ significantly

56 ses, including hospital utilization rates of parenteral anticoagulation for AF as an instrument for a

57 Among patients with AF during sepsis, parenteral anticoagulation was not associated with reduc

58 A growing number are on either oral or parenteral anticoagulation, but the impact of anticoagul

59 oembolism initially treated (5-21 days) with parenteral anticoagulation, requiring anticoagulation th

60 were associated with increased completion of parenteral antimicrobial therapy (64.08% vs 46.15%; odds

61 04 clinical practice guideline on outpatient parenteral antimicrobial therapy (OPAT) [1].

62 04 clinical practice guideline on outpatient parenteral antimicrobial therapy (OPAT) [1].

63 Outpatient parenteral antimicrobial therapy (OPAT) can be managed b

64 elop quality indicators (QIs) for outpatient parenteral antimicrobial therapy (OPAT) care that can be

65 Outpatient parenteral antimicrobial therapy (OPAT) is a widely used

66 Outpatient parenteral antimicrobial therapy (OPAT) is a widely-used

67 Outpatient parenteral antimicrobial therapy (OPAT) is accepted as s

68 Outpatient parenteral antimicrobial therapy (OPAT) programs allow p

69 Research is limited on combining outpatient parenteral antimicrobial therapy (OPAT) with addiction t

70 home infusion; patients requiring outpatient parenteral antimicrobial therapy must seek treatment in

71 ne 2017 to May 2018 in a regional outpatient parenteral antimicrobial therapy population.

72 Outpatient parenteral antimicrobial therapy with addiction treatmen

73 n innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine trea

74 al therapies on an outpatient basis, such as parenteral antimicrobial therapy.

75 mission in 384 patients receiving outpatient parenteral antimicrobial therapy.

76 al MS medications need to be administered by parenteral application but are modestly effective.

77 Parenteral application of Nano-mupirocin in a murine mod

78 Parenteral ARS is associated with a risk of delayed anem

79 both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen with the standard five-dose regim

80 th severe P. falciparum malaria treated with parenteral artesunate followed by an oral artemisinin-co

81 Patient fatality rates even with parenteral artesunate treatment remain high.

82 Patients were randomly assigned to receive parenteral ascorbic acid (1500 mg), hydrocortisone (50 m

83 nal vaccination and heterologous boosting of parenteral BCG immunisation.

84 However, parenteral BCG-prime-Apa-subunit-boost by a homologous r

85 ho can receive either orally administered or parenteral (bortezomib-based) therapy.

86 The success of recent clinical trials for LA parenteral cabotegravir and rilpivirine highlight the em

87 Institute guideline-adherent (macrolide with parenteral cephalosporin) vs non-guideline-adherent anti

88 26,867 members exposed to 487,630 courses of parenteral cephalosporins over the 3-year study period.

89 , and standard combination therapy as use of parenteral colistin-carbapenem or colistin-tigecycline f

90 han or equal to 10% improvement in FEV1 with parenteral corticosteroid.

91 Depot parenteral corticosteroids are not recommended for treat

92 Are oral or parenteral corticosteroids associated with improved clin

93 symptoms between SA and NONSA persist after parenteral corticosteroids, suggesting a component of co

94 s a worsening asthma event requiring oral or parenteral corticosteroids.

95 concerns regarding potential immunogenicity, parenteral delivery, and cost.

96 and liposomes to encapsulate such gasses for parenteral delivery.

97 ay vaccination induces greater efficacy than parenteral delivery; in both conventional vaccination an

98 Although effective, parenteral desensitization regimens require use of costl

99 A regimen of parenteral dextrose infusion that delays PH-induced hypo

100 urrently in clinical development all require parenteral drug administration.

101 formed in accordance with the pharmacopoeia, Parenteral Drug Association and International Organisati

102 feasibility of developing IVIVCs for complex parenteral drug products such as peptide microspheres.

103 ted and may be considered for development as parenteral drugs.

104 tially protected against mortality following parenteral endotoxin administration.

105 posures (95% CI, 1/1,428,571-1/96,154) and 8 parenteral exposures (95% CI, 1/200,000-1/35,971) (P = .

106 ering peptide therapeutics to women in a non-parenteral fashion as demonstrated by both blood levels

107 Parenteral fish-oil (FO) therapy is a safe and effective

108 sion and/or replacing the soybean oil with a parenteral fish-oil lipid emulsion or emulsions of mixed

109 or 48 hours, while receiving protocol-guided parenteral fluids and a norepinephrine infusion to maint

110 Defining the qualitative sameness of parenteral formulations comprised of poly(lactide-co-gly

111 ormulations, but also for developing generic parenteral formulations that are required to have the sa

112 rd for in vitro drug dissolution studies for parenteral formulations.

113 w fluoroquinolone available in both oral and parenteral formulations.

114 +/- 2.2 days versus 16.7 +/- 2.3 days in the parenteral group (P = 0.007).

115 were no significant differences between the parenteral group and the enteral group in the mean numbe

116 ons were also significantly increased in the parenteral group at day 1 (p < 0.001) and day 5 (p = 0.0

117 glutamine concentrations were higher in the parenteral group than in the enteral group on postoperat

118 was significantly higher in the enteral and parenteral groups than in the control group [median (IQR

119 treated with vitamin K antagonists (48.4%), parenteral heparins (27.7%), and direct oral anticoagula

120 zation, making the comparison of mucosal and parenteral immunization difficult.

121 Parenteral immunization of dams with heat-inactivated C.

122 ses of lower magnitude than those induced by parenteral immunization, making the comparison of mucosa

123 Parenteral immunization, specifically subcutaneous and i

124 s that is superior to protection provided by parenteral immunization.

125 enzymes and the ability of oocysts to cause parenteral infections, the present study investigated th

126 ompromised by the need to administer them by parenteral injection.

127 t 1220pg/ml, i.e. levels typically following parenteral injections of leuprolide.

128 We aimed to evaluate the efficacy of the parenteral (intravenous or intramuscular) ondansetron vs

129 Administration of parenteral iron did not improve the phenotype.

130 a potential for harm from increasing use of parenteral iron in dialysis-dependent patients.

131 subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the tr

132 with minor infusion reactions observed with parenteral iron.

133 Long-Acting Parenterals (LAPs) have been used in the clinic to provi

134 ished data that evaluate these strategies in parenteral lipid management for the treatment and preven

135 ades, novel strategies for the management of parenteral lipids have improved morbidity and mortality

136 histopathological resolution after course of parenteral Liposomal Amphotercin B.

137 Use of a beta-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) se

138 bilirubin magnified the association between parenteral manganese and decreasing T1R.

139 ted the hypothesis that infants with greater parenteral manganese exposure have higher brain manganes

140 ed by MR imaging, than do infants with lower parenteral manganese exposure.

141 iation of relaxometry indexes with total and parenteral manganese exposures.

142 Infants exposed to parenteral manganese were enrolled in a prospective coho

143 controlled trial to evaluate the efficacy of parenteral methotrexate (25 mg/wk) in 111 patients with

144 Parenteral methotrexate is an effective treatment for pa

145 In a randomized controlled trial, parenteral methotrexate was not superior to placebo for

146 ty, and predictability of IVIVCs for complex parenteral microspheres containing a variety of therapeu

147 Parenteral non-replicating rotavirus vaccines might offe

148 Moreover, parenteral NSAIDs were associated with much higher risk

149 ry drugs use during ARI episodes, especially parenteral NSAIDs, was associated with a further increas

150 vs 17.5%, RR: 0.2, CI: 0.09-0.5), and total parenteral nutrition (3.9% vs 22.5%, RR: 0.2, CI: 0.07-0

151 17.5%; RR, 0.2 [95% CI, .09-.5]), and total parenteral nutrition (3.9% vs 22.5%; RR, 0.2 [95% CI, .0

152 3%), prolonged drainage (67.8%), and enteral/parenteral nutrition (54.7%).

153 ared with 18.5% in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% con

154 ntion) by nasojejunal tube (n = 61) or early parenteral nutrition (early parenteral nutrition, contro

155 Home parenteral nutrition (HPN) and intestinal transplantatio

156 We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the

157 ts with CIPO with end-stage disease and home parenteral nutrition (HPN)-associated complications.

158 ial in adult inpatients receiving enteral or parenteral nutrition (or both) who required subcutaneous

159 The use of total parenteral nutrition (p = 0.03), longer duration of anti

160 rase and alkaline phosphatase than was early parenteral nutrition (P=0.001 and P=0.04, respectively),

161 echanical ventilatory support than was early parenteral nutrition (P=0.001), as well as a smaller pro

162 Long-term parenteral nutrition (PN) carries the risk of progressiv

163 The impact of dilatation on parenteral nutrition (PN) dependence and survival has no

164 Standard trace element-supplemented neonatal parenteral nutrition (PN) has a high manganese content a

165 lant sterols, including stigmasterol, during parenteral nutrition (PN) have been linked with serum bi

166 IFALD) is a common complication of long-term parenteral nutrition (PN) in children and adults.

167 Efforts to optimize early parenteral nutrition (PN) in extremely low-birth-weight

168 Parenteral nutrition (PN) increases risks of infections

169 Parenteral nutrition (PN) is the main treatment for inte

170 ns (ILEs) are used as a monotherapy to treat parenteral nutrition (PN)-associated liver disease and p

171 ldren with intestinal failure (IF) depend on parenteral nutrition (PN).

172 habilitation that necessitate chronic use of parenteral nutrition (PN).

173 ection for mesenteric infarction may require parenteral nutrition (PN).

174 with short bowel syndrome (SBS) who require parenteral nutrition (PN).

175 rving growth and development with the use of parenteral nutrition (PN).

176 Total parenteral nutrition (TPN) is an invasive and advanced r

177 Total parenteral nutrition (TPN) is commonly used clinically t

178 l early enteral nutrition (NJEEN) with total parenteral nutrition (TPN), after pancreaticoduodenectom

179 We utilized a model of total parenteral nutrition (TPN), or enteral nutrient deprivat

180 Mice that received total parenteral nutrition (TPN), which deprives the animals o

181 of gut failure (GF) with the need for total parenteral nutrition (TPN).

182 dependence on enteral tube feeding or total parenteral nutrition [odds ratio (OR) 4.30, 95% confiden

183 ation and patient survival, both on extended parenteral nutrition and after transplantation, have imp

184 Enteral or parenteral nutrition before, during, and after CABG may

185 with insulin did not lower glucagon, whereas parenteral nutrition containing amino acids increased gl

186 Patients who remained parenteral nutrition dependent were more likely to have

187 children to investigate whether withholding parenteral nutrition for 1 week (i.e., providing late pa

188 In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinicall

189 an or equal to 13, expected to require total parenteral nutrition for at least 5 days.

190 Patients with SBS who suffer from IF require parenteral nutrition for survival, but long-term parente

191 35%) of those who were alive at 28 days were parenteral nutrition free.

192 trials have questioned the benefit of early parenteral nutrition in adults.

193 guidelines recommend the use of enteral over parenteral nutrition in patients undergoing gastrointest

194 with intestinal failure expected to require parenteral nutrition indefinitely.

195 Parenteral nutrition is central to the care of very imma

196 nteral nutrition for survival, but long-term parenteral nutrition may lead to complications such as c

197 The effect of early parenteral nutrition on clinical outcomes in critically

198 (stratified by type of nutritional support [parenteral nutrition on or off] and pre-study total dail

199 n therapy in inpatients receiving enteral or parenteral nutrition or both.

200 Patients received total parenteral nutrition prepared either with a lipid emulsi

201 omputing anatomy of reconstructed gut, total parenteral nutrition requirements, cause of GF, and seru

202 e cancer setting, and $78513.83 for the home parenteral nutrition setting per CLABSI episode prevente

203 ent setting, and a 92.73% chance in the home parenteral nutrition setting.

204 Total parenteral nutrition should be considered only in cases

205 Enteral feeding tubes and parenteral nutrition should not be used routinely.

206 Is parenteral nutrition via peripherally inserted central c

207 Compared with short peripheral cannulas, parenteral nutrition via PICCs is associated with better

208 Late parenteral nutrition was also associated with lower plas

209 Late parenteral nutrition was associated with a shorter durat

210 Early parenteral nutrition was given as control nutrition to o

211 tients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 hours after

212 atients receiving late parenteral nutrition, parenteral nutrition was not provided until the morning

213 modeled was the probability of weaning from parenteral nutrition while on teduglutide.

214 upports increased supplementation of preterm parenteral nutrition with both choline and PUFAs.

215 l nutrition for 1 week (i.e., providing late parenteral nutrition) in the pediatric intensive care un

216 gs (hemodialysis, cancer treatment, and home parenteral nutrition), antimicrobial lock solutions are

217 utaneous drainage, antibiotics at discharge, parenteral nutrition, and an extended hospital length of

218 itive function, decreased functional status, parenteral nutrition, and pressure ulcers.

219 iglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins.

220 ection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% in the grou

221 s 6.5+/-0.4 days in the group receiving late parenteral nutrition, as compared with 9.2+/-0.8 days in

222 n = 61) or early parenteral nutrition (early parenteral nutrition, control) by jugular vein catheter

223 oeconomic status, sex, and number of days on parenteral nutrition, higher stressful life events score

224 For the 723 patients receiving early parenteral nutrition, parenteral nutrition was initiated

225 whereas for the 717 patients receiving late parenteral nutrition, parenteral nutrition was not provi

226 When compared with lipid-free parenteral nutrition, patients who received fish oil had

227 Calorie delivery from enteral nutrition, parenteral nutrition, propofol, and dextrose containing

228 titis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and cysti

229 A total of 500 patients with total parenteral nutrition-dependent catastrophic and chronic

230 once biochemical cholestasis is detected in parenteral nutrition-dependent patients is recommended.

231 sed for augmentation of energy absorption in parenteral nutrition-dependent subjects with short bowel

232 post-surfactant and increasing early use of parenteral nutrition.

233 infants who are typically supported by total parenteral nutrition.

234 U) is clinically superior to providing early parenteral nutrition.

235 U was clinically superior to providing early parenteral nutrition.

236 c dependence on central venous catheters for parenteral nutrition.

237 e a promising therapy to allow autonomy from parenteral nutrition.

238 stinal failure experiencing complications of parenteral nutrition.

239 reatening complications related to long-term parenteral nutrition.

240 nservatively with dietary measures and total parenteral nutrition.

241 gs: hemodialysis, cancer treatment, and home parenteral nutrition.

242 nitiation of enteral (oral or tube feeds) or parenteral nutrition; avoidance of any unwanted hypocarb

243 9.2+/-0.8 days in the group receiving early parenteral nutrition; there was also a higher likelihood

244 scharge from the ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23;

245 d trials (RCTs) have investigated enteral or parenteral nutritional support, and evidence-based clini

246 vomiting, was compared in cases who received parenteral ondansetron and in cases who received traditi

247 Parenteral ondansetron is significantly more effective t

248 A total of 66 patients were included: 37 had parenteral ondansetron, 14 were treated with traditional

249 FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) t

250 f Ebola virus (EBOV) infection primarily use parenteral or aerosol routes of exposure.

251 fic T-cell response peaked 32-52 weeks after parenteral or mucosal BCG-priming but waned significantl

252 ABG) were randomly assigned between enteral, parenteral, or no nutrition (control) from 2 d before, d

253 y 30 mug, then 60 mug if doses tolerated) to parenteral P2-VP8-P[8] subunit rotavirus or placebo inje

254 INTERPRETATION: The parenteral P2-VP8-P[8] vaccine was well tolerated and im

255 asing, potentially due to a decreased use of parenteral penicillins, and because severe anaphylactic

256 especially for complex drug products such as parenteral PLGA microspheres with multiphasic drug relea

257 f in vitro-in vivo correlations (IVIVCs) for parenteral polymeric microspheres has been very challeng

258 C for complex non-oral dosage forms (such as parenteral polymeric microspheres/implants, and transder

259 able to improve the protective outcome over parenteral prime/airway boost.

260 mbolus after TAVR and to investigate whether parenteral procedural anticoagulation strategies affect

261 Thus, implantable devices and long-acting parenteral prodrugs have emerged which may provide more

262 Parenteral replenishment of the vitamin B-12 store in de

263 alamin in humans and to assess the effect of parenteral replenishment of vitamin B-12 on the bioavail

264 th high and low oral doses, before and after parenteral replenishment of vitamin B-12 stores, from th

265 Participants were interviewed regarding parenteral risk behaviours and exposure to services rece

266 We hypothesized that delivery through the parenteral route is superior to that through the enteral

267 ivery platforms could provide an alternative parenteral route of esketamine dosing in patients.

268 NP delivery is often via the parenteral route, reliant on administration using hypode

269 livery of VV vaccine in Hu-mice, but not the parenteral route, significantly reduces the humanlike lu

270 cine administered via respiratory mucosal or parenteral route.

271 didate vaccines are administered through the parenteral route.

272 therapy via the respiratory mucosal, but not parenteral, route significantly accelerates pulmonary my

273 ract generally limit their administration to parenteral routes.

274 erapy, including exclusive use of an oral or parenteral second- or third-generation cephalosporin, pe

275 ent of PNALD include restricting the dose of parenteral soybean oil lipid emulsion and/or replacing t

276 : the adjusted odds ratio (aOR) of receiving parenteral steroids was 14.48 (95% confidence interval [

277 th intestinal failure who are receiving home parenteral support (HPS), catheter-related bloodstream i

278 estinal failure (IF), who are receiving home parenteral support (HPS), variations between centers in

279 e, intestinal failure (IF) and dependence on parenteral support (PS) have been defined objectively as

280 However, the effects of teduglutide on parenteral support vary among patients.

281 tion with teduglutide treatment and baseline parenteral support volume (y = -0.3870x + 90.0279, r(2)

282 These findings may inform initial parenteral support volume adjustments and management of

283 ncrease urine production and reduce need for parenteral support volume in patients with short bowel s

284 We correlated parenteral support volume reduction with teduglutide tre

285 whom teduglutide has the largest effects on parenteral support volume response.

286 Changes in parenteral support volume were evaluated according to ba

287 The effects of teduglutide on absolute parenteral support volume were significantly greater in

288 on patients with SBS, we associated reduced parenteral support volume with baseline parenteral suppo

289 volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejun

290 uced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS featur

291 investigated this issue by using a model of parenteral TB immunization and intravascular immunostain

292 ion for many vulnerable patients who receive parenteral therapies on an outpatient basis, such as par

293 he value of local point-of-care diagnostics, parenteral therapies, and electrolyte replacement in EVD

294 zolid is a promising alternative to standard parenteral therapy (SPT) in Staphylococcus aureus bacter

295 n of infants, many of whom require long-term parenteral therapy and intestinal rehabilitation.

296 abine plus cedazuridine as an alternative to parenteral therapy or in combination with other new oral

297 Parenteral transmission is a potential mode of acute HEV

298 luated and compared the efficacy of oral and parenteral treatments for SUNCT and SUNA in a real-world

299 Parenteral vaccination can reduce O157 shedding in cattl

300 ts clinical development of CDC-9 for oral or parenteral vaccination in children.